Antineoplastics
1
Reactions 1083 - 7 Jan 2006 S Antineoplastics Secondary haematological malignancies following breast cancer therapy: 6 case reports Six women developed secondary haematological malignancies after receiving antineoplastic therapy [dosages not stated] for breast cancer. [See table for patient details.] Patient characteristics and treatment details Patient Age Antineoplastics Duration Secondary (years) (cycles) malignancy 1 51 Cyclophosphamide, 8 AML epirubicin, fluorouracil. 2 57 Cyclophosphamide, 6 AML epirubicin, fluorouracil. Paclitaxel, 1 . cisplatin. 3 50 Cyclophosphamide, 6 MDS doxorubicin, fluorouracil, tamoxifen. 4 62 Cyclophosphamide, 6 DLBL methotrexate, fluorouracil. 5 55 Cyclophosphamide, 6 Lymphoma epirubicin, fluorouracil. 6 62 Cyclophosphamide, 4 Mantle cell methotrexate, lymphoma fluorouracil. AML, acute myeloid leukaemia; MDS, myelodysplastic syndrome; DLBL, diffuse large B-cell lymphoma Patient 1 presented with a fever and diarrhoea 19 months after starting antineoplastic therapy. Acute myeloid leukaemia (AML) was diagnosed and she received cytarabine, daunorubicin, mitoxantrone and granulocyte colony- stimulating factors. However, she died following disease progression. Patient 2 presented with general weakness, fatigue and dizziness 52 months after starting antineoplastic therapy and was diagnosed with AML. She received supportive care and died 8 months later as a result of pneumonia and sepsis. Patient 3 was diagnosed with myelodysplastic syndrome approximately 1 year after starting antineoplastic therapy. Despite treatment with cytarabine, daunorubicin, mitoxantrone and granulocyte colony-stimulating factors, leukaemic transformation occurred and she died following disease progression. Patient 4 presented with a tonsilar mass 4 years after starting antineoplastic therapy, and was diagnosed with a diffuse large B-cell lymphoma. She received cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP), with complete response. Patient 5 presented with lower abdominal pain and palpable lymph nodes on her neck 7 months after starting antineoplastic therapy. Angioimmunoblastic T-cell lymphoma was diagnosed and she received CHOP. However, she subsequently died of sepsis. Patient 6 presented with a left inguinal mass 13 years after receiving antineoplastic therapy. Mantle cell lymphoma with bone marrow infiltration was diagnosed. A partial response was achieved with CHOP. Park MJ, et al. Secondary hematological malignancies after breast cancer chemotherapy. Leukemia and Lymphoma 46: 1183-1188, No. 8, Aug 2005 - South Korea 801030447 1 Reactions 7 Jan 2006 No. 1083 0114-9954/10/1083-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1083 - 7 Jan 2006
SAntineoplastics
Secondary haematological malignancies followingbreast cancer therapy: 6 case reports
Six women developed secondary haematologicalmalignancies after receiving antineoplastic therapy [dosagesnot stated] for breast cancer. [See table for patient details.]
Patient characteristics and treatment detailsPatient Age Antineoplastics Duration Secondary
(years) (cycles) malignancy
1 51 Cyclophosphamide, 8 AMLepirubicin,
fluorouracil.2 57 Cyclophosphamide, 6 AML
epirubicin,fluorouracil.Paclitaxel, 1 .cisplatin.
3 50 Cyclophosphamide, 6 MDSdoxorubicin,fluorouracil,tamoxifen.
4 62 Cyclophosphamide, 6 DLBLmethotrexate,fluorouracil.
5 55 Cyclophosphamide, 6 Lymphomaepirubicin,
fluorouracil.6 62 Cyclophosphamide, 4 Mantle cell
methotrexate, lymphomafluorouracil.
AML, acute myeloid leukaemia; MDS, myelodysplastic syndrome; DLBL,diffuse large B-cell lymphoma
Patient 1 presented with a fever and diarrhoea 19 monthsafter starting antineoplastic therapy. Acute myeloid leukaemia(AML) was diagnosed and she received cytarabine,daunorubicin, mitoxantrone and granulocyte colony-stimulating factors. However, she died following diseaseprogression.
Patient 2 presented with general weakness, fatigue anddizziness 52 months after starting antineoplastic therapy andwas diagnosed with AML. She received supportive care anddied 8 months later as a result of pneumonia and sepsis.
Patient 3 was diagnosed with myelodysplastic syndromeapproximately 1 year after starting antineoplastic therapy.Despite treatment with cytarabine, daunorubicin,mitoxantrone and granulocyte colony-stimulating factors,leukaemic transformation occurred and she died followingdisease progression.
Patient 4 presented with a tonsilar mass 4 years after startingantineoplastic therapy, and was diagnosed with a diffuse largeB-cell lymphoma. She received cyclophosphamide,doxorubicin, vincristine and prednisolone (CHOP), withcomplete response.
Patient 5 presented with lower abdominal pain and palpablelymph nodes on her neck 7 months after startingantineoplastic therapy. Angioimmunoblastic T-cell lymphomawas diagnosed and she received CHOP. However, shesubsequently died of sepsis.
Patient 6 presented with a left inguinal mass 13 years afterreceiving antineoplastic therapy. Mantle cell lymphoma withbone marrow infiltration was diagnosed. A partial responsewas achieved with CHOP.Park MJ, et al. Secondary hematological malignancies after breast cancerchemotherapy. Leukemia and Lymphoma 46: 1183-1188, No. 8, Aug 2005 - SouthKorea 801030447
1
Reactions 7 Jan 2006 No. 10830114-9954/10/1083-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
